34206945|t|Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?
34206945|a|Schizophrenia typically emerges during adolescence, with progression from an ultra-high risk state (UHR) to the first episode of psychosis (FEP) followed by a chronic phase. The detailed pathophysiology of schizophrenia and the factors leading to progression across these stages remain relatively unknown. The current treatment relies on antipsychotics, which are effective for FEP and chronic schizophrenia but ineffective for UHR patients. Antipsychotics modulate dopaminergic and glutamatergic neurotransmission, inflammation, oxidative stress, and membrane lipids pathways. Many of these biological pathways intercommunicate and play a role in schizophrenia pathophysiology. In this context, research of preventive treatment in early stages has explored the antipsychotic effects of omega-3 supplementation in UHR and FEP patients. This review summarizes the action of omega-3 in various biological systems involved in schizophrenia. Similar to antipsychotics, omega-3 supplementation reduces inflammation and oxidative stress, improves myelination, modifies the properties of cell membranes, and influences dopamine and glutamate pathways. Omega-3 supplementation also modulates one-carbon metabolism, the endocannabinoid system, and appears to present neuroprotective properties. Omega-3 has little side effects compared to antipsychotics and may be safely prescribed for UHR patients and as an add-on for FEP patients. This could to lead to more efficacious individualised treatments, thus contributing to precision medicine in psychiatry.
34206945	54	73	Omega-3 Fatty Acids	Chemical	MESH:D015525
34206945	93	106	Schizophrenia	Disease	MESH:D012559
34206945	129	142	Schizophrenia	Disease	MESH:D012559
34206945	258	267	psychosis	Disease	MESH:D011618
34206945	269	272	FEP	Disease	MESH:D011618
34206945	335	348	schizophrenia	Disease	MESH:D012559
34206945	507	510	FEP	Disease	MESH:D011618
34206945	523	536	schizophrenia	Disease	MESH:D012559
34206945	561	569	patients	Species	9606
34206945	645	657	inflammation	Disease	MESH:D007249
34206945	690	696	lipids	Chemical	MESH:D008055
34206945	777	790	schizophrenia	Disease	MESH:D012559
34206945	916	923	omega-3	Chemical	MESH:D015525
34206945	951	954	FEP	Disease	MESH:D011618
34206945	955	963	patients	Species	9606
34206945	1052	1065	schizophrenia	Disease	MESH:D012559
34206945	1094	1101	omega-3	Chemical	MESH:D015525
34206945	1126	1138	inflammation	Disease	MESH:D007249
34206945	1241	1249	dopamine	Chemical	MESH:D004298
34206945	1254	1263	glutamate	Chemical	MESH:D018698
34206945	1274	1281	Omega-3	Chemical	MESH:D015525
34206945	1340	1355	endocannabinoid	Chemical	MESH:D063388
34206945	1415	1422	Omega-3	Chemical	MESH:D015525
34206945	1511	1519	patients	Species	9606
34206945	1541	1544	FEP	Disease	MESH:D011618
34206945	1545	1553	patients	Species	9606
34206945	Association	MESH:D015525	MESH:D012559
34206945	Negative_Correlation	MESH:D015525	MESH:D011618
34206945	Association	MESH:D015525	MESH:D063388
34206945	Negative_Correlation	MESH:D015525	MESH:D007249
34206945	Association	MESH:D015525	MESH:D018698
34206945	Association	MESH:D004298	MESH:D015525

